Literature DB >> 29341161

Modalities for image- and molecular-guided cancer surgery.

M A Stammes1,2, S L Bugby3, T Porta4, K Pierzchalski4, T Devling5, C Otto6, J Dijkstra1, A L Vahrmeijer7, L-F de Geus-Oei1,8, J S D Mieog7.   

Abstract

BACKGROUND: Surgery is the cornerstone of treatment for many solid tumours. A wide variety of imaging modalities are available before surgery for staging, although surgeons still rely primarily on visual and haptic cues in the operating environment. Image and molecular guidance might improve the adequacy of resection through enhanced tumour definition and detection of aberrant deposits. Intraoperative modalities available for image- and molecular-guided cancer surgery are reviewed here.
METHODS: Intraoperative cancer detection techniques were identified through a systematic literature search, with selection of peer-reviewed publications from January 2012 to January 2017. Modalities were reviewed, described and compared according to 25 predefined characteristics. To summarize the data in a comparable way, a three-point rating scale was applied to quantitative characteristics.
RESULTS: The search identified ten image- and molecular-guided surgery techniques, which can be divided into four groups: conventional, optical, nuclear and endogenous reflectance modalities. Conventional techniques are the most well known imaging modalities, but unfortunately have the drawback of a defined resolution and long acquisition time. Optical imaging is a real-time modality; however, the penetration depth is limited. Nuclear modalities have excellent penetration depth, but their intraoperative use is limited by the use of radioactivity. Endogenous reflectance modalities provide high resolution, although with a narrow field of view.
CONCLUSION: Each modality has its strengths and weaknesses; no single technique will be suitable for all surgical procedures. Strict selection of modalities per cancer type and surgical requirements is required as well as combining techniques to find the optimal balance.
© 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 29341161     DOI: 10.1002/bjs.10789

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

Review 1.  Repurposing Molecular Imaging and Sensing for Cancer Image-Guided Surgery.

Authors:  Suman B Mondal; Christine M O'Brien; Kevin Bishop; Ryan C Fields; Julie A Margenthaler; Samuel Achilefu
Journal:  J Nucl Med       Date:  2020-04-17       Impact factor: 10.057

Review 2.  Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.

Authors:  Shuya Yano; Hiroshi Tazawa; Hiroyuki Kishimoto; Shunsuke Kagawa; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

3.  Recommendations for Standardizing Thorax PET-CT in Non-Human Primates by Recent Experience from Macaque Studies.

Authors:  Marieke A Stammes; Jaco Bakker; Richard A W Vervenne; Dian G M Zijlmans; Leo van Geest; Michel P M Vierboom; Jan A M Langermans; Frank A W Verreck
Journal:  Animals (Basel)       Date:  2021-01-15       Impact factor: 2.752

4.  High-precision tumor resection down to few-cell level guided by NIR-IIb molecular fluorescence imaging.

Authors:  Feifei Wang; Liangqiong Qu; Fuqiang Ren; Ani Baghdasaryan; Yingying Jiang; RuSiou Hsu; Peng Liang; Jiachen Li; Guanzhou Zhu; Zhuoran Ma; Hongjie Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-05       Impact factor: 12.779

Review 5.  Near-infrared fluorescence guided surgery: State of the evidence from a health technology assessment perspective.

Authors:  Tibor Géczi; Zsolt Simonka; Judit Lantos; Melinda Wetzel; Zsolt Szabó; György Lázár; József Furák
Journal:  Front Surg       Date:  2022-07-26

Review 6.  A practical guide for the use of indocyanine green and methylene blue in fluorescence-guided abdominal surgery.

Authors:  Labrinus van Manen; Henricus J M Handgraaf; Michele Diana; Jouke Dijkstra; Takeaki Ishizawa; Alexander L Vahrmeijer; Jan Sven David Mieog
Journal:  J Surg Oncol       Date:  2018-06-24       Impact factor: 3.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.